ANVISA
Anvisa alerts to risks of “slimming pens” and debate on therapeutic alternatives grows
Anvisa discusses review of regulation of medicinal cannabis products
Anvisa to hold public hearing on regulatory framework for herbal medicines
Lula's nominee for director-president of Anvisa awaits Senate confirmation hearing
Bruno Pegoraro presents report on hemp to Minister Carlos Fávaro and coordinates regulation in Brazil
08/02/2025Report from the Ficus Institute highlights the economic and environmental potential of industrial hemp
Unicamp Group and Pharmacy Council Suggest Nearly 30 Changes to the Regulation of Medicinal Cannabis Use in Brazil
27/05/2025Group responds to public consultation and proposes changes including an increase in the THC limit and expansion of cannabinoid manipulation
Anvisa removes the revision of RDC 327/2019 from the Collegiate Board meeting agenda
19/12/2024Update of the RDC included in the Regulatory Agenda 2024-2025 is expected for next year
Anvisa to vote on draft regulation on the cultivation of cannabis this Wednesday (14)
13/05/2025Draft discussed in a meeting with a YouTube broadcast contains points on THC limit, Sanitary control execution, import and export, destination of the cultivated plant among others
Anvisa prohibits mushroom products sold by company that markets 18,000 units per month
02/07/2025Agency determined the prohibition of manufacturing, marketing, and use of mushroom-based supplements produced by Mush Mush Club Ltda.
Anvisa announces mandatory information in SNGPC for 2025
18/11/2024Anvisa informs that, in 2025, the inclusion of data in the SNGPC will be mandatory. Pharmacy professionals have until December 31 to test the tool and clarify doubts
Anvisa presents rules for commercial cultivation of cannabis maintaining low THC content for the pharmaceutical industry
28/01/2026Proposal authorizes companies to cultivate plants with up to 0.3% THC exclusively for the production of medicinal inputs, but experts warn of the technical unfeasibility of the limit in a tropical climate
Regulation of Cannabis Products for Medicinal Purposes Enters Anvisa's Regulatory Agenda 2024-2025
28/11/2024Review of the Brazilian Pharmacopoeia collegiates is also included in the Agenda
“The cycle is now national”: Anvisa's CEO details new milestone in cannabis cultivation and predicts up to 60% cost reduction
10/02/2026In an interview with the CB.Poder program of Correio Brasiliense, conducted by journalists Adriana Bernardes and Sibele Negromonte, Leandro Safatle, acting CEO of Anvisa, detailed the behind-the-scenes and expectations regarding the new regulation of medicinal cannabis and research in Brazil
Anvisa proposes new RDC for medicinal cannabis products and maintains RDC 660 out of the review
28/01/2026Anvisa's proposal establishes a new regulatory framework for industrialized medicinal cannabis products in Brazil
Follow Live: Anvisa now debates revision of RDC 327 and cultivation
28/01/2026Anvisa directors meet this Wednesday (28) to discuss the update of medicinal cannabis regulations; learn how to follow
Follow Live: Anvisa now debates review of RDC 327 and cultivation
28/01/2026Anvisa directors meet this Wednesday (28) to discuss the update of medicinal cannabis regulations; learn how to follow